Leukocytapheresis (LCAP) for treating refractory adult-onset Still’s disease (AOSD)

References

• Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salu-sinsky-Sternbach M, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine. 1991;70: 118–36.
   Google Scholar
• Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis. 2006;65:564–72.
   PubMed Web of Science ®Google Scholar
• Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheu-matol. 2008;22:773–92.
   PubMed Web of Science ®Google Scholar
• Hot A, Toh ML, Coppéré B, Perard L, Madoux MH, Mausservey C, et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case—control study of 8 patients. Medicine. 2010;89: 37–46.
   Google Scholar
• Coffernils M, Soupart A, Pradier 0, Feremans W, Nève P, Decaux G. Hyperferritinemia in adult onset Still's disease and the hemophagocytic syndrome. J Rheumatol. 1992;19:1425–7.
   Google Scholar
• Efthimiou P, Kontzias A, Ward CM, Ogden NS. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol. 2007;3:328-35.
   Google Scholar
• Fautrel B, Sibilia J, Mariette X, Combe B, Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64: 262–6.
   Google Scholar
• Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Kataharada K, Ishizuka T, et al. Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1999;42:431–7.
   Google Scholar
• Izumi Y, Tominaga M, Iwanaga N, Huang M, Tanaka F, Aratake K, et al. Twenty-four-week follow-up examination of a leuko-cytapheresis therapy in rheumatoid arthritis. Mod Rheumatol. 2006;16:20–3.
   PubMedGoogle Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19:424–30.
   PubMed Web of Science ®Google Scholar
• Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, et al. Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006;65:1596–601.
   PubMed Web of Science ®Google Scholar
• Wulffraat NM. Defining criteria for macrophage activation syn-drome, a process towards early recognition and treatment. J Rheumatol. 2011;38:593–4.
   PubMedGoogle Scholar
• Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheu-matol. 2010;22:561–6.
   PubMed Web of Science ®Google Scholar
• Davi S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011;38:764–8.
   PubMed Web of Science ®Google Scholar
• Omagari K, Matsunaga Y, Yamashita H, Nishiyama H, Hazama H, Oda H, et al. Successful treatment with cyclosporin in adult-onset Still disease manifesting as acute hepatitis with marked hyperferritinemia. Am J Med Sci. 2003;326:148–51.
   PubMed Web of Science ®Google Scholar
• Kötter I, Wacker A, Koch S, Henes J, Richter C, Engel A, et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007;37:189–97.
   Google Scholar
• Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52:1794–803.
   Google Scholar
• Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad 0, Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP), Club Rhumatismes et Inflammation (CRI), et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: pre-liminary experience in France. Ann Rheum Dis. 2008;67: 302–8.
   Google Scholar
• Yoshimura M, Makiyama J, Koga T, Miyashita T, Izumi Y, Torigoshi T, et al. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD). Clin Exp Rheumatol. 2010;28:141–2.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21:92–6.
   Google Scholar
• Hahn G, Stuhlmiiller B, Hain N, Kalden JR, Pfizenmaier K, Burmester GR. Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy. J Clin Invest. 1993;91:862–70.
   PubMed Web of Science ®Google Scholar
• Hidaka T, Suzuki K, Kawakami M, Okada M, Kataharada K, Shinohara T, et al. Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J Clin Apher. 2001;16:74–81.
   PubMed Web of Science ®Google Scholar
• Andoh A, Ogawa A, Kitamura K, Inatomi 0, Fujino S, Tsujikawa T, et al. Suppression of interleukin-lbeta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapher-esis therapy in patients with ulcerative colitis. J Gastroenterol. 2004;39:1150–7.
   Google Scholar
• Tanaka H, Tsugawa K, Nakahata T, Suzuki K, Ito E. Leukocy-tapheresis for the treatment of refractory systemic-onset juvenile idiopathic arthritis. Clin Rheumatol. 2007;26:1014–6.
   Google Scholar